157 related articles for article (PubMed ID: 18509835)
1. Diffusion of interferon beta in Iran and its utilization in Tehran.
Palesh M; Jonsson PM; Jamshidi H; Wettermark B; Tomson G; Fredrikson S
Pharmacoepidemiol Drug Saf; 2008 Sep; 17(9):934-41. PubMed ID: 18509835
[TBL] [Abstract][Full Text] [Related]
2. A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study.
Elhami SR; Mohammad K; Sahraian MA; Eftekhar H
Neuroepidemiology; 2011; 36(3):141-7. PubMed ID: 21508646
[TBL] [Abstract][Full Text] [Related]
3. Frequency of myasthenia gravis in multiple sclerosis: Report of five cases from Isfahan, Iran.
Basiri K; Etemadifar M; Maghzi AH; Zarghami N
Neurol India; 2009; 57(5):638-40. PubMed ID: 19934567
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis in Isfahan, Iran.
Saadatnia M; Etemadifar M; Maghzi AH
Int Rev Neurobiol; 2007; 79():357-75. PubMed ID: 17531850
[TBL] [Abstract][Full Text] [Related]
5. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
[TBL] [Abstract][Full Text] [Related]
7. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran.
Etemadifar M; Maghzi AH
Mult Scler; 2011 Aug; 17(8):1022-7. PubMed ID: 21459809
[TBL] [Abstract][Full Text] [Related]
8. Interferon-beta(1b) treatment in neuromyelitis optica.
Tanaka M; Tanaka K; Komori M
Eur Neurol; 2009; 62(3):167-70. PubMed ID: 19590215
[TBL] [Abstract][Full Text] [Related]
9. Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study.
Maghzi AH; Ghazavi H; Ahsan M; Etemadifar M; Mousavi S; Khorvash F; Minagar A
Mult Scler; 2010 Mar; 16(3):359-61. PubMed ID: 20086021
[TBL] [Abstract][Full Text] [Related]
10. Clinical parameters to predict response to interferon in relapsing multiple sclerosis.
Fromont A; Debouverie M; Le Teuff G; Quantin C; Binquet C; Moreau T
Neuroepidemiology; 2008; 31(3):150-6. PubMed ID: 18716412
[TBL] [Abstract][Full Text] [Related]
11. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
[TBL] [Abstract][Full Text] [Related]
13. Diffusion of magnetic resonance imaging in Iran.
Palesh M; Fredrikson S; Jamshidi H; Jonsson PM; Tomson G
Int J Technol Assess Health Care; 2007; 23(2):278-85. PubMed ID: 17493315
[TBL] [Abstract][Full Text] [Related]
14. [Place of residence determines access to interferon-beta therapy in MS. Less than 15 per cent of patients are treated--big differences between the counties].
Andersson A; Persson PM; Fredrikson S
Lakartidningen; 1999 Dec; 96(49):5492-5. PubMed ID: 10643243
[TBL] [Abstract][Full Text] [Related]
15. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
Drulovic J; Savic E; Pekmezovic T; Mesaros S; Stojsavljevic N; Dujmovic-Basuroski I; Kostic J; Vasic V; Mostarica Stojkovic M; Popadic D
J Neuroimmunol; 2009 Oct; 215(1-2):90-5. PubMed ID: 19695714
[TBL] [Abstract][Full Text] [Related]
16. [Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)].
Hernandez-Perez MA;
Rev Neurol; 2009 May 16-31; 48(10):505-8. PubMed ID: 19434583
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
18. Glypican 5 is an interferon-beta response gene: a replication study.
Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
[TBL] [Abstract][Full Text] [Related]
19. Drug therapies for the treatment of multiple sclerosis.
Ryan M
J Infus Nurs; 2009; 32(3):137-44. PubMed ID: 19444021
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
